Jiangsu Hengrui Medicine Co., Ltd. (SHA: 600276)

China flag China · Delayed Price · Currency is CNY
44.40
-0.60 (-1.33%)
Sep 6, 2024, 3:00 PM CST
8.61%
Market Cap 282.32B
Revenue (ttm) 25.25B
Net Income (ttm) 5.43B
Shares Out 6.36B
EPS (ttm) 0.86
PE Ratio 51.54
Forward PE 48.07
Dividend 0.20 (0.45%)
Ex-Dividend Date Jul 12, 2024
Volume 14,147,570
Open 45.15
Previous Close 45.00
Day's Range 44.40 - 45.15
52-Week Range 35.51 - 49.74
Beta 0.23
Analysts n/a
Price Target n/a
Earnings Date Oct 25, 2024

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-... [Read more]

Sector Healthcare
Founded 1970
Employees 19,611
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600276
Full Company Profile

Financial Performance

In 2023, 600276's revenue was 22.82 billion, an increase of 7.26% compared to the previous year's 21.28 billion. Earnings were 4.30 billion, an increase of 10.14%.

Financial Statements

News

There is no news available yet.